Not normally something to be confident about. Is there something in particular about the post hoc analysis that would give comfort about the lead drug moving forward? BTW, if memory serves I believe Altus was spun out of VRTX many years ago.
Would be interesting to know what type of sales that drug is doing. Based on CEO's bio (http://www.allenapharma.com/leadership-team ), I'm guessing that Alnara was the company that he started and sold to LLY in 2010 for the drug for pancreatic insufficiency.
Not sure I'm following what you're saying here. Are you saying you're skeptical because the entire pipeline is tied to Altus?